Cas:351002-82-9 Boc-α-(4-methylbenzyl)-DL-Pro-OH manufacturer & supplier

Chemical Name:Boc-α-(4-methylbenzyl)-DL-Pro-OH

CAS.NO:351002-82-9

Synonyms:2-(4-Methylbenzyl)-1-{[(2-methyl-2-propanyl)oxy]carbonyl}proline

Molecular Formula:C₁₈H₂₅NO₄

Molecular Weight:319.39500

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:457.2ºC at 760 mmHg

Density:1.173g/cm3

Index of Refraction:1.55

PSA:66.84000

Exact Mass:319.17800

LogP:3.32970

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like 2-(4-Methylbenzyl)-1-{[(2-methyl-2-propanyl)oxy]carbonyl}proline chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-(4-Methylbenzyl)-1-{[(2-methyl-2-propanyl)oxy]carbonyl}proline physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-(4-Methylbenzyl)-1-{[(2-methyl-2-propanyl)oxy]carbonyl}proline Use and application,2-(4-Methylbenzyl)-1-{[(2-methyl-2-propanyl)oxy]carbonyl}proline technical grade,usp/ep/jp grade.

Related News: An effective treatment for Alzheimer��s, which is estimated in 60%-70% of around 50 million dementia cases worldwide, could become one of the best-selling drugs globally. Boc-α-(4-methylbenzyl)-DL-Pro-OH manufacturer As the global generic drug market booms and the international API industry accelerates its transfer to developing countries, China and India rely on cost advantages to rapidly grow into major API producers and exporters. Boc-α-(4-methylbenzyl)-DL-Pro-OH supplier An effective treatment for Alzheimer��s, which is estimated in 60%-70% of around 50 million dementia cases worldwide, could become one of the best-selling drugs globally. Boc-α-(4-methylbenzyl)-DL-Pro-OH vendor Capacity: the bottleneck of business growth, expanding capacity and increasing utilization become a trend. Capacity is the core factor that determines the supply capacity of API companies. Insufficient capacity will cause companies to selectively complete orders and produce varieties, limiting the expansion of API products and market development. Boc-α-(4-methylbenzyl)-DL-Pro-OH factory The vaccine also proved safe during the two-year trial, in which eleven doses were administered to randomly chosen patients with mild dementia. People who received the vaccine, known as AADvac1, experienced about the same numbers of side effects and adverse events as those who were given a placebo.